News Boehringer collaborates with Autifony on schizophrenia drug Deal could be worth 627.5 million euros
News BMS settles US off-label marketing case for $19.5m BMS illegally promoted schizophrenia drug, says attorney general
News Lundbeck/Otsuka look for new use of mental health drug Companies want new bipolar disorder use for Abilify Maintena.
News Janssen's quarterly schizophrenia drug approved in EU Company hopes new formulation will improve patient outcomes.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
